Overview |
bs-2424R-Cy3 |
KCNH1 Polyclonal Antibody, Cy3 Conjugated |
WB, FCM, IF(IHC-P), IF(IHC-F), IF(ICC) |
Human, Mouse |
Rat, Dog, Cow, Pig, Horse, Rabbit |
Specifications |
Cy3 |
Rabbit |
KLH conjugated synthetic peptide derived from human KCNH1 |
501-600/989 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
Target |
3756 |
Cell membrane |
EAG1; EAG 1; EAG-1; KCNH 1; KCNH-1; h eag; Kv10.1; MGC124420; MGC142269; EAG; Ether a go go potassium channel 1; hEAG1; M eag; MGC124419; Potassium voltage gated channel subfamily H eag related, member 1; Voltage gated potassium channel subunit Kv10.1; KCNH1_HUMAN. |
Voltage-gated potassium (Kv) channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. This gene encodes a member of the potassium channel, voltage-gated, subfamily H. This member is a pore-forming (alpha) subunit of a voltage-gated non-inactivating delayed rectifier potassium channel. It is activated at the onset of myoblast differentiation. The gene is highly expressed in brain and in myoblasts. Overexpression of the gene may confer a growth advantage to cancer cells and favor tumor cell proliferation. Alternative splicing of this gene results in two transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2008]. |
Application Dilution |
WB |
1:300-5000 |
FCM |
1:20-100 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |